Estrogen-withdrawal migraine. I. Duration of exposure required and attempted prophylaxis by premenstrual estrogen administration.
The minimum exposure to estrogen required to cause estrogen-withdrawal migraine has been studied by giving long-acting estradiol valerate to four women and short-acting estradiol benzoate to two women. It was found that several days of exposure to high estrogen levels were needed to cause migraine on estrogen withdrawal. Oral administration of estrogen supplements in the form of estradiol valerate or as conjugated equine estrogens during the premenstrual phase in four women did not significantly affect plasma levels of estradiol, nor was it effective in preventing menstrual migraine.
D004958:Estradiol / Q000097:blood* / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008599:Menstruation Disturbances / Q000209:etiology*; D008881:Migraine Disorders / Q000097:blood / Q000209:etiology*; D013375:Substance Withdrawal Syndrome / Q000628:therapy; D013997:Time Factors
D004958:Estradiol